No potential conflict of interest relevant to this letter was reported.
Drs. Kahn and Eilber both report having received research funding from Boston Scientific. No other potential conflict of interest relevant to this letter was reported.
New England Journal of Medicine 385(17):p e60(1), October 21, 2021. | DOI: 10.1056/NEJMc2112378